A 24-month, Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of Fingolimod 1.25 mg and 0.5 mg Administered Orally Once Daily Versus Placebo in Patients With Relapsing-remitting Multiple Sclerosis

Trial Profile

A 24-month, Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of Fingolimod 1.25 mg and 0.5 mg Administered Orally Once Daily Versus Placebo in Patients With Relapsing-remitting Multiple Sclerosis

Completed
Phase of Trial: Phase III

Latest Information Update: 27 Jun 2017

At a glance

  • Drugs Fingolimod (Primary)
  • Indications Multiple sclerosis
  • Focus Registrational; Therapeutic Use
  • Acronyms FREEDOMS
  • Sponsors Novartis
  • Most Recent Events

    • 27 Jun 2017 Results assessing the effect of Fingolimod on Neurofilament Light Chain Blood Levels in patients from two phase III trials (FREEDOMS, TRANSFORMS; n=387) compared with healthy subjects (n=35), presented at the 3rd Congress of the European Academy of Neurology
    • 28 Apr 2017 Results of pooled analysis of two core studies and their respective extension studies presented at the 69th Annual Meeting of the American Academy of Neurology
    • 28 Apr 2017 Results of exploratory biomarker analysis using blood samples of patients from the fingolimod phase 3 clinical studies (TRANSFORMS (n=222), FREEDOMS (n=164) and healthy controls (n=35)), presented at the 69th Annual Meeting of the American Academy of Neurology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top